175 related articles for article (PubMed ID: 38638439)
21. A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption.
Pokhrel NK; Kim YG; Kim HJ; Kim HJ; Lee JH; Choi SY; Kwon TG; Lee HJ; Kim JY; Lee Y
J Periodontol; 2019 May; 90(5):546-554. PubMed ID: 30387495
[TBL] [Abstract][Full Text] [Related]
22. The protective effect of Geniposide on diabetic cognitive impairment through BTK/TLR4/NF-κB pathway.
Liu S; Zheng M; Li Y; He L; Chen T
Psychopharmacology (Berl); 2020 Feb; 237(2):465-477. PubMed ID: 31811349
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
24. Bruton's tyrosine kinase ablation inhibits B cell responses and antibody production for the prevention of chronic rejection in cardiac transplantation.
Han F; Shi X; Liao T; Zhang W; Ma M; Leng Q; Jiang W; Na N; Miao Y; Huang Z
Clin Immunol; 2024 Apr; 261():109941. PubMed ID: 38365047
[TBL] [Abstract][Full Text] [Related]
25. Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity.
Middendorp S; Dingjan GM; Maas A; Dahlenborg K; Hendriks RW
J Immunol; 2003 Dec; 171(11):5988-96. PubMed ID: 14634110
[TBL] [Abstract][Full Text] [Related]
26. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
27. Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells.
Lee KG; Xu S; Wong ET; Tergaonkar V; Lam KP
J Biol Chem; 2008 Apr; 283(17):11189-98. PubMed ID: 18276597
[TBL] [Abstract][Full Text] [Related]
28. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
29. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
30. Inhibitor of Bruton's tyrosine kinases, PCI-32765, decreases pro-inflammatory mediators' production in high glucose-induced macrophages.
Fan Z; Wang Y; Xu X; Wu Y
Int Immunopharmacol; 2018 May; 58():145-153. PubMed ID: 29587203
[TBL] [Abstract][Full Text] [Related]
31. Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Alqahtani F; Alanazi WA; Mahmood HM; Alsanea S; Attia SM
Int Immunopharmacol; 2021 Jan; 90():107123. PubMed ID: 33168411
[TBL] [Abstract][Full Text] [Related]
32. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
[TBL] [Abstract][Full Text] [Related]
34. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
35. Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide.
Doyle SL; Jefferies CA; O'Neill LA
J Biol Chem; 2005 Jun; 280(25):23496-501. PubMed ID: 15849198
[TBL] [Abstract][Full Text] [Related]
36. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Spriano F; Tarantelli C; Gaudio E; Gerlach MM; Priebe V; Cascione L; Bernasconi E; Targa A; Mascia M; Dirnhofer S; Stathis A; Zucca E; Bertoni F
Br J Haematol; 2019 Dec; 187(5):595-601. PubMed ID: 31355927
[TBL] [Abstract][Full Text] [Related]
37. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
[TBL] [Abstract][Full Text] [Related]
38. Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation.
Bajpai UD; Zhang K; Teutsch M; Sen R; Wortis HH
J Exp Med; 2000 May; 191(10):1735-44. PubMed ID: 10811866
[TBL] [Abstract][Full Text] [Related]
39. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib treatment improves T cell number and function in CLL patients.
Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
